# Atea Pharmaceuticals, Inc. clinical trials: 33 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 33 trials with Atea Pharmaceuticals, Inc. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Atea Pharmaceuticals, Inc.: 33 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/atea-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 33
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 33, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 27, 2026 | NCT07728487 | Study of AT-587 in Healthy Subjects | Atea Pharmaceuticals, Inc. | Phase 1 | Recruiting | Hepatitis E | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728487) |
| January 2, 2026 | NCT07314346 | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314346) |
| December 9, 2025 | NCT07272889 | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07272889) |
| June 25, 2025 | NCT07037277 | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV | Atea Pharmaceuticals, Inc. | Phase 3 | Active not recruiting | HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C | 880 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07037277) |
| June 6, 2025 | NCT07007806 | Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07007806) |
| April 10, 2025 | NCT06921941 | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06921941) |
| April 4, 2025 | NCT06911320 | Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study, Hepatic Impairment, Renal Impairment | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06911320) |
| March 10, 2025 | NCT06868264 | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV | Atea Pharmaceuticals, Inc. | Phase 3 | Completed | HEPATITIS C VIRUS CHRONIC INFECTION | 940 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06868264) |
| April 10, 2024 | NCT06356194 | Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06356194) |
| January 12, 2024 | NCT06204679 | Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06204679) |
| June 15, 2023 | NCT05905497 | The Study of Bemnifosbuvir in Healthy Japanese Subjects | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05905497) |
| June 15, 2023 | NCT05905484 | Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05905484) |
| June 15, 2023 | NCT05904470 | A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV | Atea Pharmaceuticals, Inc. | Phase 2 | Completed | Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis, HCV | 275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05904470) |
| February 16, 2023 | NCT05731843 | Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05731843) |
| February 13, 2023 | NCT05724693 | Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer, Hepatic Impairment | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05724693) |
| November 29, 2022 | NCT05629962 | SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 | Atea Pharmaceuticals, Inc. | Phase 3 | Completed | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19 | 2,285 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05629962) |
| November 16, 2022 | NCT05618314 | Study of AT-527 in Subjects With Normal and Impaired Renal Function | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer, Renal Impairment | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05618314) |
| July 20, 2022 | NCT05466240 | Study of AT-752 in Patients With Dengue Infection | Atea Pharmaceuticals, Inc. | Phase 2 | Terminated | Dengue Fever | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05466240) |
| May 9, 2022 | NCT05366439 | Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model | Atea Pharmaceuticals, Inc. | Phase 1 | Terminated | Dengue | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05366439) |
| February 25, 2022 | NCT05256732 | Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05256732) |
| December 10, 2021 | NCT05154123 | Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05154123) |
| November 30, 2021 | NCT05137626 | Drug-drug Interaction Study of Digoxin and AT-527 (R07496998) | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteers Study | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05137626) |
| August 13, 2021 | NCT05004415 | Mass Balance Study of AT-527 in Healthy Adult Male Subjects (R07496998) | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05004415) |
| May 7, 2021 | NCT04877769 | Bronchopulmonary PK of AT-527 (R07496998) | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04877769) |
| April 29, 2021 | NCT04865445 | Drug-drug Interaction Study of Midazolam and AT-527 (R07496998) | Atea Pharmaceuticals, Inc. | Phase 1 | Completed | Healthy Volunteer Study | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04865445) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 25 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 3 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 27 |
| Terminated | 3 |
| Withdrawn | 1 |
| Active not recruiting | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hepatitis C | 5 |
| Hepatitis C, Chronic | 5 |
| Dengue | 3 |
| COVID-19 | 2 |
| Renal Insufficiency | 2 |
| Vector Borne Diseases | 1 |
| Infections | 1 |
| Virus Diseases | 1 |
| Hemorrhagic Fevers, Viral | 1 |
| Liver Diseases | 1 |
| Hepatitis, Viral, Human | 1 |
| Flaviviridae Infections | 1 |
| Liver Cirrhosis | 1 |
| Hepatitis E | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Japanese restaurants in the United States](https://specstream.ai/data/businesses/japanese-restaurants/united-states)
- [Engineering schools in the United States](https://specstream.ai/data/businesses/engineering-schools/united-states)
- [Brazilian restaurants in the United States](https://specstream.ai/data/businesses/brazilian-restaurants/united-states)
- [Vending machine suppliers in the United States](https://specstream.ai/data/businesses/vending-machine-suppliers/united-states)
- [Psychiatry practices in the United States](https://specstream.ai/data/businesses/psychiatry-practices/united-states)
